RYMGX Rydex S&P MidCap 400 Pure Growth A Forecast, Technical & Fundamental Analysis

The most notable companies in this group are Arrowhead Pharmaceuticals (NASDAQ:ARWR).

The investment seeks investment results that match, the performance of the S&P MidCap 400® Pure Growth Index for mid-cap growth securities on a daily basis. The fund will invest at least 80% of its net assets, plus any borrowings for investment purposes, in securities of companies in the underlying index and derivatives and other instruments whose performance is expected to correspond to that of the underlying index. The index is composed of those constituents of the S&P MidCap 400® that exhibit the strongest growth characteristics as measured using three factors: sales growth,ratio of earnings change to price, and momentum. The fund is non-diversified.

The average market capitalization across the Rydex S&P MidCap 400 Pure Growth A MF is 16.68B. The market cap for tickers in the group ranges from 8.34B to 28.24B. FTI holds the highest valuation in this group at 28.24B. The lowest valued company is IDCC at 8.34B.

The average weekly volume growth across all stocks in the Rydex S&P MidCap 400 Pure Growth A MF was 133%. For the same stocks of the MF, the average monthly volume growth was 100% and the average quarterly volume growth was -64%